by Jen Hodson | May 9, 2017 | Uncategorized
The NANT Cancer Vaccine, The First Simultaneous Combination of Off the Shelf Natural Killer Cells (NK) With Endogenous Adaptive Dendritic, T Cell and NK Cell Activation. Personalized Molecular Informed Therapy with NantHealth’s GPS Cancer as The Complementary...
by Jen Hodson | May 4, 2017 | Uncategorized
American Society of Clinical Oncology (ASCO) Annual Meeting 53rd Annual Meeting 2017 June 2-6, 2017 McCormick Place Chicago, IL Learn...
by Jen Hodson | Apr 4, 2017 | Uncategorized
Culver City and San Diego, CA April 4, 2017 - NantKwest, Inc. (Nasdaq:NK) and Viracta Therapeutics, Inc. announced the initial closing of a Series B Preferred financing round of up to $18.4 million with NantKwest, Inc. [NASDAQ:NK] as the lead investor. Joining...
by Jen Hodson | Mar 20, 2017 | Uncategorized
CULVER CITY, Calif.–Mar. 20, 2017- NantKwest, Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases...
by Jen Hodson | Mar 6, 2017 | Uncategorized
CULVER CITY, CALIFORNIA-(BUSINESS WIRE), MARCH 3, 2016 NantKwest (Nasdaq:NK) today announced that members of the company’s management team will be presenting at the following upcoming investor conferences: Cowen & Company’s 37th Annual Healthcare Conference...
by Jen Hodson | Jan 23, 2017 | Uncategorized
CULVER CITY, Calif.–(BUSINESS WIRE)–Jan. 23, 2017- NantKwest Inc. (Nasdaq:NK), a pioneering, next-generation, clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat cancer,...
